This invention relates to methods of treating the prodrome and adult onset stage of Huntingtons disease or symptoms thereof, and or Juvenile Huntingtons disease symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration.
